NICE does not recommend AbbVie’s leukaemia drug
16 February 2017 | By Niamh Marriott, Digital Editor
The incremental cost-effectiveness ratios (ICERs) for venetoclax compared with best supportive care were higher than the normally range...
List view / Grid view
16 February 2017 | By Niamh Marriott, Digital Editor
The incremental cost-effectiveness ratios (ICERs) for venetoclax compared with best supportive care were higher than the normally range...
3 February 2017 | By Niamh Marriott, Digital Editor
NICE has today published draft guidance which does not recommend Pfizer's breast cancer drug palbociclib for routine funding on the NHS...
12 January 2017 | By Niamh Marriott, Digital Editor
Everolimus (Afinitor, Novartis) is now recommended to be available on the NHS as a treatment option for some patients with advanced renal cell carcinoma...
29 December 2016 | By Niamh Louise Marriott, Digital Editor
Trastuzumab emtansine is currently being funded through the Cancer Drugs Fund (CDF). NICE is looking again at its 2015 guidance to see whether it should...
20 December 2016 | By Niamh Louise Marriott, Digital Editor
The National Institute of Health and Care Excellence (NICE) and the United States’ Food and Drug Administration (FDA) will team up, using technology to...
5 December 2016 | By Niamh Louise Marriott, Digital Editor
In earlier draft guidance, NICE’s appraisal committee had not recommended pembrolizumab as there were uncertainties about its long term benefits...
5 December 2016 | By Niamh Louise Marriott, Digital Editor
Mepolizumab is the first biologic treatment to target specific white blood cells called eosinophils, which are responsible for symptoms of severe asthma...
2 December 2016 | By Niamh Louise Marriott, Digital Editor
Ibrutinib had only previously been available through the CDF. Following a reduction in its price for the NHS, it is now recommended in further guidance...
21 November 2016 | By Niamh Louise Marriott, Digital Content Producer
FITs are considered to be accurate because unlike other tests, they use immunochemical detection methods that are specific to human haemoglobin...
21 November 2016 | By Niamh Louise Marriott, Digital Content Producer
A discount to the price of pertuzumab agreed with the company was an important factor in enabling NICE to overturn its earlier provisional decision...
17 November 2016 | By Niamh Louise Marriott, Digital Content Producer
More than 75% of treatments in the Cancer Drugs Fund (CDF) which have been reappraised by the National Institute for Health and Care Excellence (NICE) have received positive recommendations for routine use in the NHS. NICE has been reappraising cancer drugs which had not been recommended in previous NICE guidance…
14 November 2016 | By Norma McGough, Director of Policy, Research & Campaigns, Coeliac UK
Coeliac UK’s Director of Policy, Research & Campaigns, Norma McGough, welcomes NICE’s new quality standards on coeliac disease, which she believes will bring clarity and improvement to diagnosis screening and better access to long term treatment…
10 November 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE recommends 2 cancer drugs for routine use on the NHS as part of its programme to appraise treatments that were available on the Cancer Drugs Fund...
7 November 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE was reconsidering cetuximab as part of its programme to appraise drugs that are currently available on the Cancer Drugs Fund...
3 November 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE has said eribulin, which is also called Halaven and made by Eisai, should be an option for people with locally advanced or metastatic breast cancer...